Efficacy of CDX-1140, an agonist CD40 antibody, in preclinical tumor models

被引：1
|
作者：
Thomas, Lawrence J. [1 ]
He, Li-Zhen [2 ]
Testa, James [2 ]
Wasiuk, Anna [2 ]
Weidlick, Jeffrey [2 ]
Sisson, Crystal [2 ]
Vitale, Laura A. [2 ]
O'Neill, Thomas [2 ]
Forsberg, Eric [1 ]
Pilsmaker, Catherine D. [1 ]
Gergel, Lauren E. [1 ]
Do, Elizabeth Q. [1 ]
Boyer, James [1 ]
Baronas, April R. [1 ]
Rocheleau, Mallary [1 ]
Grealish, Michelle E. [1 ]
Borrelli, Kathleen M. [1 ]
Marsh, Henry C. [1 ]
Keler, Tibor [2 ]
机构：
[1] Celldex Therapeut Inc, Needham, MA USA
[2] Celldex Therapeut Inc, Hampton, NJ USA
来源：
CANCER RESEARCH | 2018年 / 78卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2018-3816
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3816
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Development of CDX-1140, an agonist CD40 antibody for cancer immunotherapy
    Laura A. Vitale
    Lawrence J. Thomas
    Li-Zhen He
    Thomas O’Neill
    Jenifer Widger
    Andrea Crocker
    Karuna Sundarapandiyan
    James R. Storey
    Eric M. Forsberg
    Jeffrey Weidlick
    April R. Baronas
    Lauren E. Gergel
    James M. Boyer
    Crystal Sisson
    Joel Goldstein
    Henry C. Marsh
    Tibor Keler
    Cancer Immunology, Immunotherapy, 2019, 68 : 233 - 245
  • [2] Development of CDX-1140, an agonist CD40 antibody for cancer immunotherapy
    Thomas, Lawrence
    Vitale, Laura
    O'Neill, Thomas
    Widger, Jenifer
    Crocker, Andrea
    He, Li-Zhen
    Weidlick, Jeffrey
    Sundarapandiyan, Karuna
    Storey, James
    Forsberg, Eric
    Pilsmaker, Catherine
    Gergel, Lauren
    Do, Elizabeth
    Goldstein, Joel
    Marsh, Henry
    Keler, Tibor
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [3] Development of CDX-1140, an agonist CD40 antibody for cancer immunotherapy
    Vitale, Laura A.
    Thomas, Lawrence J.
    He, Li-Zhen
    O'Neill, Thomas
    Widger, Jenifer
    Crocker, Andrea
    Sundarapandiyan, Karuna
    Storey, James R.
    Forsberg, Eric M.
    Weidlick, Jeffrey
    Baronas, April R.
    Gergel, Lauren E.
    Boyer, James M.
    Sisson, Crystal
    Goldstein, Joel
    Marsh, Henry C., Jr.
    Keler, Tibor
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2019, 68 (02) : 233 - 245
  • [4] CDX-1140, a Novel Agonist CD40 Antibody with Potent Anti-Lymphoma Activity
    He, Li-Zhen
    Testa, James
    Anna, Wasiuk
    Jeffery, Weidlick
    Sisson, Crystal
    Vitale, Laura A.
    O'Neill, Thomas
    Crocker, Andrea
    Widger, Jenifer
    Goldstein, Joel
    Marsh, Henry C., Jr.
    Keler, Tibor
    BLOOD, 2016, 128 (22)
  • [5] Phase 1 study of the CD40 agonist monoclonal antibody (mAb) CDX-1140 alone and in combination with CDX-301 (rhFLT3L) in patients with advanced cancers
    Sanborn, Rachel
    Gabrail, Nashat
    O'Hara, Mark
    Bhardwaj, Nina
    Gordon, Michael
    Hauke, Ralph
    Bordoni, Rodolfo
    Khalil, Danny
    Rawls, Tracey
    Vitale, Laura
    Gedrich, Richard
    Hawthorne, Thomas
    Keler, Tibor
    Forsberg, Eirc
    Thomas, Lawrence
    Yellin, Michael
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [6] RESULTS FROM A PHASE 1 STUDY OF CDX-1140, A FULLY HUMAN ANTI-CD40 AGONIST MONOCLONAL ANTIBODY (MAB), IN COMBINATION WITH PEMBROLIZUMAB
    Sanborn, Rachel
    Gabrail, Nashat
    Carneiro, Benedito
    O'Hara, Mark
    Bordoni, Rodolfo
    Gordon, Michael
    Khalil, Danny
    Hauke, Ralph
    Taglienti, Cherie
    Rogalski, Mark
    Styles, Rachel
    Alvarado, Diego
    Maurer, Deena
    Crew, Linda
    Keler, Tibor
    Yellin, Michael
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A624 - A624
  • [7] First-in-human Phase I study of the CD40 agonist mAb CDX-1140 and in combination with CDX-301 (rhFLT3L) in patients with advanced cancers: Interim results
    Sanborn, Rachel E.
    Gabrail, Nashat Y.
    Bhardwaj, Nina
    Gordon, Michael S.
    O'Hara, Mark
    Khalil, Danny
    Hawthorne, Thomas
    Gedrich, Richard
    Vitale, Laura
    Rogalski, Mark
    Li, Tianshu
    Rawls, Tracey
    Keler, Tibor
    Yellin, Michael
    CANCER RESEARCH, 2019, 79 (13)
  • [8] AJ17 potentiates agonist CD40 antibody efficacy and attenuates agonist CD40 induced PD-L1 expression and associated toxicity in murine tumor models
    Gaur, Vidit
    Barnwal, Anjali
    Ateeq, Bushra
    Bhattacharyya, Jayanta
    CANCER RESEARCH, 2023, 83 (07)
  • [9] Intratumoral Nanofluidic System for Enhancing Tumor Biodistribution of Agonist CD40 Antibody
    Chua, Corrine Ying Xuan
    Ho, Jeremy
    Susnjar, Antonia
    Lolli, Graziano
    Di Trani, Nicola
    Pesaresi, Federica
    Zhang, Mengying
    Nance, Elizabeth
    Grattoni, Alessandro
    ADVANCED THERAPEUTICS, 2020, 3 (10)
  • [10] In vivo efficacy of the CD40 agonist antibody CP-870,893 against a broad range of tumor types: Impact of tumor CD40 expression, dendritic cells, and chemotherapy.
    Gladue, R. P.
    Cole, S. H.
    Donovan, C.
    Paradis, T.
    Alpert, R.
    Natoli, E.
    Bedian, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 103S - 103S
12345